Summit Creek Advisors’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-172,081
Closed -$8.3M 73
2021
Q1
$8.3M Sell
172,081
-597
-0.3% -$31.1K 0.99% 46
2020
Q4
$9.3M Sell
172,678
-9,680
-5% -$437K 1.19% 41
2020
Q3
$6.73M Sell
182,358
-56,100
-24% -$2.09M 1% 46
2020
Q2
$7.39M Sell
238,458
-570
-0.2% -$15.8K 1.09% 43
2020
Q1
$6.6M Sell
239,028
-122,830
-34% -$3.68M 1.32% 36
2019
Q4
$10.6M Sell
361,858
-2,040
-0.6% -$48.6K 1.65% 31
2019
Q3
$6.96M Buy
363,898
+15,690
+5% +$368K 1.17% 40
2019
Q2
$7.64M Buy
348,208
+960
+0.3% +$21.1K 1.28% 38
2019
Q1
$7.11M Sell
347,248
-171,320
-33% -$2.98M 1.27% 41
2018
Q4
$6.54M Sell
518,568
-504,132
-49% -$7.51M 1.32% 41
2018
Q3
$15.7M Sell
1,022,700
-3,750
-0.4% -$51.8K 2.51% 14
2018
Q2
$13.5M Sell
1,026,450
-95,410
-9% -$1.05M 2.42% 14
2018
Q1
$9.15M Buy
1,121,860
+90
+0% +$729 1.66% 29
2017
Q4
$9.94M Sell
1,121,770
-10,805
-1% -$99.6K 1.87% 26
2017
Q3
$12.6M Sell
1,132,575
-8,661
-0.8% -$84.3K 2.48% 13
2017
Q2
$10.2M Buy
1,141,236
+193,371
+20% +$1.53M 2.11% 19
2017
Q1
$7.48M Sell
947,865
-317,614
-25% -$2.59M 1.57% 34
2016
Q4
$10.8M Buy
1,265,479
+155
+0% +$1.33K 1.86% 27
2016
Q3
$10.4M Buy
1,265,324
+222,525
+21% +$1.87M 1.7% 34
2016
Q2
$8.38M Buy
1,042,799
+178,770
+21% +$1.43M 1.42% 37
2016
Q1
$5.82M Buy
864,029
+55,428
+7% +$365K 0.92% 45
2015
Q4
$6.36M Buy
808,601
+275,551
+52% +$2.02M 1.06% 42
2015
Q3
$3.05M Buy
+533,050
New +$3.3M 0.5% 50

Other funds holding NEO

Summit Creek Advisors's NEO Position: Q2 2021 in Review

Summit Creek Advisors sold out of NeoGenomics (NEO) in Q2 2021, closing a stake of 172,081 shares — an estimated $8.3M sold.

Summit Creek Advisors first reported a position in NEO in Q3 2015 and held it in 23 quarters. The position peaked at $15.7M in Q3 2018. 311 funds tracked by Wall St. Rank hold NEO as of Q2 2021.

  • Summit Creek Advisors reported no remaining NeoGenomics position as of Q2 2021 after selling out during the quarter.
  • Summit Creek Advisors sold 172,081 NeoGenomics shares in Q2 2021, an estimated $8.3M.
  • Summit Creek Advisors first reported a position in NeoGenomics in Q3 2015 and held it in 23 quarters.
  • Summit Creek Advisors's NeoGenomics position peaked at $15.7M in Q3 2018.
  • 311 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2021.

Based on Summit Creek Advisors's 13F filing for Q2 2021, filed 4 Aug 2021.